Transgene S.A. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
62.08 M |
Public Float |
- |
Transgene S.A. | |
Stock Exchange | Euronext Paris |
EPS |
EUR0.13 |
Market Cap |
EUR202.98 M |
Shares Outstanding |
83.27 M |
Public Float |
23.75 M |
Address |
400 Boulevard Gonthier dAndernach Strasbourg Alsace 67405 France |
Employees | - |
Website | http://www.transgene.fr |
Updated | 07/08/2019 |
Transgene SA is a biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. Its products include TG4010, Pexa-Vec, TG4001, TG6002, TG1050, and TG4040. The company was founded in December 1979 and is headquartered in Strasbourg, France. |